Skip to main content
Advertisement
Advertisement

QURE

QURE logo

uniQure N.V.

38.23
USD
Sponsored
-0.09
-0.23%
Sep 25, 15:59 UTC -4
Closed
exchange

After-Market

38.55

+0.32
+0.84%

QURE Earnings Reports

Positive Surprise Ratio

QURE beat 24 of 43 last estimates.

56%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$6.33M
/
-$0.94
Implied change from Q2 26 (Revenue/ EPS)
+8.41%
/
-22.95%
Implied change from Q3 25 (Revenue/ EPS)
+71.10%
/
-31.88%

uniQure N.V. earnings per share and revenue

On Jul 29, 2026, QURE reported earnings of -1.22 USD per share (EPS) for Q2 26, missing the estimate of -0.84 USD, resulting in a -45.12% surprise. Revenue reached 5.84 million, compared to an expected 5.58 million, with a 4.74% difference. The market reacted with a +9.30% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.94 USD, with revenue projected to reach 6.33 million USD, implying an decrease of -22.95% EPS, and increase of 8.41% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
logo
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
logo
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
logo
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
logo
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
logo
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
For Q2 2026, uniQure N.V. reported EPS of -$1.22, missing estimates by -45.12%, and revenue of $5.84M, 4.74% above expectations.
The stock price moved up 9.3%, changed from $36.66 before the earnings release to $40.07 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on -- analysts, uniQure N.V. is expected to report EPS of -$0.94 and revenue of $6.33M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement